Analyst consensus rating
Radiopharm Theranostics Analyst Rating: Strong Buy
Direct answer
Radiopharm Theranostics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $16.95.
Forecast evidence checked October 17, 2026.
Get free Radiopharm Theranostics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.03
- Average price target
- $16.95
- High price target
- $29.95
- Low price target
- $12.41
- Low target gap
- +1,105.2%
- Target upside
- +1,546.1%
- High target gap
- +2,807.4%
- Target range width
- 1,702.2%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Radiopharm Theranostics?
Radiopharm Theranostics has a verified Strong Buy consensus. The same dataset has an average price target of $16.95.
How far are Radiopharm Theranostics's low and high targets from the recorded price?
The low target implies +1,105.2%, while the high target implies +2,807.4%.
How many analysts are included in Radiopharm Theranostics's consensus?
The verified consensus includes 6 analysts.
How is Radiopharm Theranostics's target upside or downside calculated?
The average target of $16.95 is divided by the recorded price of $1.03, then one is subtracted to produce +1,546.1%. This does not guarantee a future return.
When was Radiopharm Theranostics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.